Growth factor treatment of stroke.
This review discusses the potential usefulness of several selected polypeptide growth factors as treatments for stroke. Distinctions between global vs. focal cerebral ischemia, permanent vs. temporary focal ischemia, and acute stroke vs. stroke recovery are first discussed. Potential routes of administration of growth factors are also considered. The growth factors basic fibroblast growth factor (bFGF), osteogenic protein-1 (OP-1), vascular endothelial growth factor (Veg-f), erythropoietin (EPO), and granulocyte colony stimulating factor (G-CSF) all show potential usefulness in animal models of acute stroke and stroke recovery. Two of these factors, bFGF and EPO, have reached human clinical trials for acute stroke, and the data are discussed. Future directions in this field are also discussed.
Ren
Jing Mei
JM
Biotrofix, Inc., Needham MA 02494, USA.
Finklestein
Seth P
SP
D000818:Animals; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage; D002545:Brain Ischemia / Q000145:classification / Q000188:drug therapy*; D004333:Drug Administration Routes; D004921:Erythropoietin / Q000008:administration & dosage*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006133:Growth Substances / Q000008:administration & dosage; D006801:Humans; D051379:Mice; D051381:Rats; D020521:Stroke / Q000145:classification / Q000188:drug therapy*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage; D042442:Vascular Endothelial Growth Factors / Q000008:administration & dosage
C525819:BMP7 protein, human; C525821:Bmp7 protein, rat; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D006133:Growth Substances; D016212:Transforming Growth Factor beta; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor